Addressing the unmet needs for patients with TP53-mutated AML

Naval Daver, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, discusses challenges in treating TP53-mutated acute myeloid leukemia (AML), emphasizing that despite advances with new drugs, this subgroup remains difficult to treat. He highlights the role of allogeneic stem cell transplantation (alloSCT) as the only intervention offering curative potential, with new immunotherapies under investigation to address the unmet need. This interview took place at the Twelfth Annual Meeting of the Society of Hematologic Oncology (SOHO 2024) congress in Houston, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.